# Li Hongsen

> Li Hongsen is a Series A investor at Golden Rain Bogor backing Biotechnology and Pharmaceutical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Golden Rain Bogor](https://shizune.co/investors/profile/golden-rain-bogor)
- Total investments: 5
- Last investment: Mar 2025
- Lead investor: 20%
- Last updated: Aug 2026

Li Hongsen is a partner of Golden Rain Bogor.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Pharmaceutical | 3 | 60% |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Manufacturing | 2 | 40% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Seed | 1 | 20% |
| Angel | 1 | 20% |
| Series B | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Butterfli | Butterfly is a manufacturer of prefilled syringes. It focuses on using the next-generation high-performance materials COC&COP to produce prefilled syringes without silicone oil systems, and is committed to breaking the international monopoly and promoting the material revolution in China's pharmaceutical packaging industry. |  | Angel | Mar 03, 2025 |  |
| Xiushi Biotechnology | Xiushi Biotechnology Focus on the R&D, production, sales, and technology development services of peptide products. | $14.2M | Seed | Oct 08, 2024 |  |
| Changsha Morning Shine | Changsha Morning Shine is an innovative pharmaceutical company that specializes in R&D outsourcing, biomedicine, chemical drugs, and biotechnology services. | $14.1M | Series A | Dec 14, 2023 |  |
| Boyi Biotechnology | Boyi Biotechnology is a technology-based firm that provides vital raw materials and complete solutions to biomedical customers in the in vitro diagnostic market. It focus on diagnostic microspheres, testing raw materials, and quality control products. | $14.1M | Series A | May 30, 2023 |  |
| ICE Bioscience | ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. | $14M | Series B | Sep 26, 2022 |  |

5 of 5 investments shown.

## Co-investors
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 1 deal together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 1 deal together
- [Bondshine Capital](https://shizune.co/investors/profile/bondshine-capital) — VC Fund, 1 deal together
- [China Growth Capital](https://shizune.co/investors/profile/china-growth-capital) — VC Fund, 1 deal together
- [China Economic Capital](https://shizune.co/investors/profile/china-national-economic-capital) — VC Fund, 1 deal together
- [Chuangjing Capital](https://shizune.co/investors/profile/chuangjing-capital) — VC Fund, 1 deal together

## About Golden Rain Bogor

VC Fund · Nanjing, China

Jinyu Bogor focuses on strategic emerging industries such as medical and pharmaceutical general health.

1 contacts available at Golden Rain Bogor.

| Name | Title | Profile |
| --- | --- | --- |
| Li Hongsen | Partner | https://shizune.co/investors/profile/li-hongsen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Li Hongsen invest in?

Li Hongsen invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Li Hongsen last invest?

The most recent investment recorded for Li Hongsen closed in Mar 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co